Back to discover
Drug

Sisomicin

In clinical development
ClassBacterial 70S ribosome inhibitorEmerging researchLate-stage development

Also known as (2S-CIS)-4-O-(3-AMINO-6-(AMINOMETHYL)-3,4-DIHYDRO-2H-PYRAN-2-YL)-2-DEOXY-6-O-(3-DEOXY-4-C-METHYL-3-(METHYLAMINO)-.BETA.-L-ARABINOPYRANOSYL)-D-STREPTAMINE, 2-DEOXY-4-O-(3-DEOXY-4-C-METHYL-3-(METHYLAMINO)-.BETA.-L-ARABINOPYRANOSYL)-6-O-(2,6-DIAMINO-2,3,4,6-TETRADEOXY-.ALPHA.-D-GLYCERO-HEX-4-ENOPYRANOSYL)-L-STREPTAMINE, O-3-DEOXY-4-C-METHYL-3-(METHYLAMINO)-.BETA-L-ARABINOPYRANOSYL-(1->4)-O-(2,6-DIAMINO-2,3,4,6-TETRADEOXY-.ALPHA.-D-GLYCERO-HEX-4-ENOPYRANOSYL-(1->6))-2-DEOXY-L-STREPTAMINE.

1
Research papers
55
Protein targets
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Sisomicin
Aliases & brands
(2S-CIS)-4-O-(3-AMINO-6-(AMINOMETHYL)-3,4-DIHYDRO-2H-PYRAN-2-YL)-2-DEOXY-6-O-(3-DEOXY-4-C-METHYL-3-(METHYLAMINO)-.BETA.-L-ARABINOPYRANOSYL)-D-STREPTAMINE2-DEOXY-4-O-(3-DEOXY-4-C-METHYL-3-(METHYLAMINO)-.BETA.-L-ARABINOPYRANOSYL)-6-O-(2,6-DIAMINO-2,3,4,6-TETRADEOXY-.ALPHA.-D-GLYCERO-HEX-4-ENOPYRANOSYL)-L-STREPTAMINEO-3-DEOXY-4-C-METHYL-3-(METHYLAMINO)-.BETA-L-ARABINOPYRANOSYL-(1->4)-O-(2,6-DIAMINO-2,3,4,6-TETRADEOXY-.ALPHA.-D-GLYCERO-HEX-4-ENOPYRANOSYL-(1->6))-2-DEOXY-L-STREPTAMINE
RxNorm CUI
9806
ChEMBL ID
CHEMBL221886
ATC codes
J01GB08
UNII
X55XSL74YQ
Primary mechanism
Bacterial 70S ribosome inhibitor

Pharmacology & targets

55 targets

Known molecular targets and mechanisms supported by curated pharmacology databases.

INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor

Clinical trials

1 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
1
registered trials across all phases
1
Late-stage (III+)
1
Discontinued
PHASE DISTRIBUTIONn = 1
Phase 41

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Sisomicin Cream Vs Nadifloxacin Cream in Primary Pyodermas

WithdrawnPH IVMerck Sharp & Dohme LLC2007

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Major research themes2
Drug Design1Drug Resistance, Multiple, Bacterial1
Journals, researchers & institutions
Top journals
  • Molecules (Basel, Switzerland)1
Leading researchers
  • Pregnolato M1
  • Taccani M1
  • Terreni M1
Leading institutions
free-text, unnormalised
  • University of Pavia1

Related drugs

7 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Acts on the same molecular target as Sisomicin, with 2 overlapping disease areas.

55 shared targets2 shared diseases1 shared paper

Studied across 2 of the same disease areas as Sisomicin in the shared literature.

2 shared diseases1 shared paper

Studied across 2 of the same disease areas as Sisomicin in the shared literature.

2 shared diseases1 shared paper

Studied across 2 of the same disease areas as Sisomicin in the shared literature.

2 shared diseases1 shared paper

Studied across 2 of the same disease areas as Sisomicin in the shared literature.

2 shared diseases1 shared paper

Studied across 2 of the same disease areas as Sisomicin in the shared literature.

2 shared diseases1 shared paper

Studied across 2 of the same disease areas as Sisomicin in the shared literature.

2 shared diseases1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials